GYNECOLOGIC CANCERS

A new analysis of a randomized phase II trial showed PARP inhibitor rucaparib slowed progression of relapsed <em>BRCA</em>-mutant ovarian cancer regardless of whether the mutations were somatic or germline.

According to a recent study, lack of clinical coverage and time off topped the perceived hindrances to gynecologic oncologists&rsquo; participation in global health activities.

The results of a new study have provided yet more evidence that survivors of endometrial cancer should be closely monitored for cardiovascular disease.

The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin has been granted a priority review designation&nbsp;by the FDA for the treatment of patients with relapsed or refractory ALL.

The much anticipated initial results of the Gynecologic Oncology Group 252 trial failed to provide additional clarity for the use of intravenous versus intraperitoneal chemotherapy in patients with ovarian cancer.

The number of futile laparotomies was reduced with diagnostic laparoscopy in patients with suspected advanced-stage ovarian cancer, according to the results of a recent study.

Douglas A. Levine, MD, discusses the relationship between <em>EMSY</em> and <em>BRCA</em>, the potential to target <em>EMSY</em> amplified tumors with PARP inhibitors, and the future of ovarian cancer treatment.

A full regulatory approval is being sought for blinatumomab as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor ALL.

Patients with endometrial cancer who receive surgery in the first 2 weeks after diagnosis have worse survival outcomes, according to a recent study.

John A. Martignetti, MD, PhD, discusses&nbsp;The Cancer Genome Atlas&#39; comprehensive, genomics-based analysis of the endometrial cancer.

Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses immune targeting in ovarian cancer.

Intentional weight loss in postmenopausal women is associated with a lower endometrial cancer risk, particularly among those with obesity, according to the results of a recent study published in the <em>Journal of Clinical Oncology</em>.<br /> &nbsp;

Philadelphia chromosome Ph&ndash;like acute lymphoblastic leukemia accounts for more than 20% of all adult patients with ALL and is associated with a poor outcome, according to findings published in the Journal of Clinical Oncology.

There is a significantly large racial disparity in hysterectomy-corrected cervical cancer mortality rates in the United States, according to a&nbsp;recent study published in <em>Cancer.</em>

The University of Texas MD Anderson Cancer Center has united with the 68 other National Cancer Institute&ndash;designated cancer centers in issuing a joint statement that endorses the recently revised vaccination recommendations from the CDC.

Carolyn E. Banister, MD, highlights the major findings of her study that discovered a new subtype of cervical cancer and the significant therapeutic implications that will follow.&nbsp;

A new drug application (NDA) for niraparib has been granted priority review by the FDA for use as a maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded to platinum-based chemotherapy, according to Tesaro, the manufacturer of the PARP 1/2 inhibitor.

The FDA has approved rucaparib (Rubraca) as a treatment for patients with&nbsp;<em>BRCA</em>-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy.

The CAR T-cell therapy CTL019 demonstrated an 82% complete remission or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, discusses the current and emerging roles of PARP inhibition in ovarian cancer.

The FDA has expanded the approval for bevacizumab (Avastin) in ovarian cancer to include patients with platinum-sensitive recurrent disease as part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to Genentech, which developed the drug.

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Significant progress is being made in the treatment of gynecologic malignancies, especially in ovarian cancer, according to Douglas A. Levine, MD.

Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended.

Findings of a new study revealed that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care (SOC) for the disease.